Synmosa Group Achieves Rapid Growth, Posts Revenue of Over NT$200 Million in a Single Month

Date:2016.02.15

Synmosa Biopharma (TPEx:4114) today announced that its revenue for January soared to more than NT$201 million (about US$6.6 million), a record high for a single month and a YoY growth of 27.1%. The excellent performance comes on the heels of Synmosa's record-breaking consolidated revenue of NT$1.778 billion (about US$58.5 million) in 2015, affirming that the company is continuing full steam ahead in 2016. Synmosa Group Chairman Peter Lin indicated that average monthly revenue in 2015 handily surpassed the company's corresponding performance in 2014, citing key products such as Actein®, Urief®, as well as the company's portfolio of cancer treatment drugs as primary drivers for growth. In addition, Synmosa's continued focus on product lines including hormonal drugs and treatments for respiratory and cardiovascular illnesses resulted in stable sales growth in 2015. These positive trends are anticipated to continue into 2016, with Synmosa expecting to again achieve record high levels of revenue.